These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Evaluation of the oral direct factor Xa inhibitor - betrixaban. Palladino M; Merli G; Thomson L Expert Opin Investig Drugs; 2013 Nov; 22(11):1465-72. PubMed ID: 23964817 [TBL] [Abstract][Full Text] [Related]
23. Increased benefit of betrixaban among patients with a history of venous thromboembolism: a post-hoc analysis of the APEX trial. Yee MK; Nafee T; Daaboul Y; Korjian S; AlKhalfan F; Kerneis M; Wiest C; Goldhaber SZ; Hernandez AF; Hull RD; Cohen AT; Harrington RA; Gibson CM J Thromb Thrombolysis; 2018 Jan; 45(1):1-8. PubMed ID: 29188425 [TBL] [Abstract][Full Text] [Related]
24. Budget impact analysis of betrixaban for venous thromboembolism prophylaxis in nonsurgical patients with acute medical illness in the United Kingdom. Guy H; Laskier V; Fisher M; Bucior I; Deitelzweig S; Cohen AT Expert Rev Pharmacoecon Outcomes Res; 2020 Jun; 20(3):259-267. PubMed ID: 31215264 [TBL] [Abstract][Full Text] [Related]
25. Cost-Effectiveness of Betrixaban Compared with Enoxaparin for Venous Thromboembolism Prophylaxis in Nonsurgical Patients with Acute Medical Illness in the United States. Guy H; Laskier V; Fisher M; Neuman WR; Bucior I; Deitelzweig S; Cohen AT Pharmacoeconomics; 2019 May; 37(5):701-714. PubMed ID: 30578462 [TBL] [Abstract][Full Text] [Related]
26. Extended-Duration Betrixaban Reduces the Risk of Rehospitalization Associated With Venous Thromboembolism Among Acutely Ill Hospitalized Medical Patients: Findings From the APEX Trial (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban Trial). Chi G; Yee MK; Amin AN; Goldhaber SZ; Hernandez AF; Hull RD; Cohen AT; Harrington RA; Gibson CM Circulation; 2018 Jan; 137(1):91-94. PubMed ID: 29279341 [No Abstract] [Full Text] [Related]
27. Association of Anemia with Venous Thromboembolism in Acutely Ill Hospitalized Patients: An APEX Trial Substudy. Chi G; Gibson CM; Hernandez AF; Hull RD; Kazmi SHA; Younes A; Walia SS; Pitliya A; Singh A; Kahe F; Kalayci A; Nafee T; Kerneis M; AlKhalfan F; Cohen AT; Harrington RA; Goldhaber SZ Am J Med; 2018 Aug; 131(8):972.e1-972.e7. PubMed ID: 29660351 [TBL] [Abstract][Full Text] [Related]
28. Symptomatic event reduction with extended-duration betrixaban in acute medically ill hospitalized patients. Gibson CM; Nafee T; Yee MK; Chi G; Korjian S; Daaboul Y; AlKhalfan F; Kerneis M; Goldhaber SZ; Hull R; Hernandez AF; Cohen AT; Harrington RA Am Heart J; 2018 Apr; 198():84-90. PubMed ID: 29653652 [TBL] [Abstract][Full Text] [Related]
29. Betrixaban - the next direct factor Xa inhibitor? Thoenes M; Minguet J; Bramlage K; Bramlage P; Ferrero C Expert Rev Hematol; 2016 Dec; 9(12):1111-1117. PubMed ID: 27809616 [TBL] [Abstract][Full Text] [Related]
33. Prevention of Venous Thromboembolism in Acutely Ill Medical Patients: A New Era. MacDougall K; Spyropoulos AC Semin Respir Crit Care Med; 2021 Apr; 42(2):308-315. PubMed ID: 33548931 [TBL] [Abstract][Full Text] [Related]
34. Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients. Cohen AT; Harrington RA; Goldhaber SZ; Hull RD; Wiens BL; Gold A; Hernandez AF; Gibson CM; N Engl J Med; 2016 Aug; 375(6):534-44. PubMed ID: 27232649 [TBL] [Abstract][Full Text] [Related]
35. Has time come for the use of direct oral anticoagulants in the extended prophylaxis of venous thromboembolism in acutely ill medical patients? Yes. Ageno W Intern Emerg Med; 2018 Oct; 13(7):1009-1013. PubMed ID: 28808888 [TBL] [Abstract][Full Text] [Related]
36. Extended prophylaxis of venous thromboembolism with betrixaban in acutely ill medical patients with and without cancer: insights from the APEX trial. Ageno W; Lopes RD; Yee MK; Hernandez A; Hull R; Goldhaber SZ; Gibson CM; Cohen AT J Thromb Thrombolysis; 2020 Feb; 49(2):214-219. PubMed ID: 31493287 [TBL] [Abstract][Full Text] [Related]
37. Current and emerging drug strategies for the prevention of venous thromboembolism in acutely ill medical inpatients. Santagata D; Cammà G; Donadini MP; Squizzato A; Ageno W Expert Opin Pharmacother; 2022 Oct; 23(14):1651-1665. PubMed ID: 36154548 [TBL] [Abstract][Full Text] [Related]